Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led to 100% complete responses in some mouse cancer models and enhanced effects when combined with anti-PD1 therapy. The findings validate Asgard's platform for turning tumors into immune-active sites and support advancing their lead gene therapy candidate, AT-108, toward clinical trials. New biomarker data for AT-108 will be presented at SITC 2026, aiding treatment monitoring and clinical development.
Asgard Therapeutics news comes alongside strong health sector momentum, with 106 of 150 US health stocks rising on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 23:12 WIB: HCA Health Inc rose 8.83% to USD 503.74 with a typical hold time of 77 days; Oscar Health Inc increased 8.30% to USD 35.10, with Pluang order activity showing 84% buy and a typical hold time of 17 days; Centene Corp gained 7.96% to USD 72.85, with a typical hold time of 43 days.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...
